Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on INT 1. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN115160306B details a high-yield DMTMM method for DPP-4 inhibitor intermediates, offering cost reduction and scalable manufacturing for reliable pharma suppliers.
Patent CN104974052B details a high-yield synthesis route for tetrahydroisoquinoline intermediates, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN108640861A enables mild macrolide production. Reduces costs and improves supply chain reliability for pharmaceutical intermediates.
Analysis of patent CN112300123B reveals a mild synthetic route for vonoprazan intermediates. This method offers significant supply chain reliability and cost reduction in pharmaceutical intermediates manufacturing.
Patent CN105111169A reveals a streamlined route for Sofosbuvir intermediates. This report analyzes cost reduction in API manufacturing and supply chain reliability for pharmaceutical partners.
Patent CN104341336B reveals a novel inorganic base route for Eliquis intermediates, offering significant cost reduction and enhanced supply chain reliability for pharmaceutical manufacturing.
Patent CN1255919A details an efficient enantioselective addition reaction for DMP-266 intermediates, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN108658930A reveals a cost-effective two-step synthesis for duloxetine intermediates. Achieve high purity and scalable production with reduced environmental impact.
Discover the advanced synthesis of Silodosin intermediates via patent CN104744336A. Achieve cost reduction in pharmaceutical intermediates manufacturing with safer, scalable routes.
Patent CN102206164A details a cleaner route for Tapentadol intermediates using PCl5 and catalytic hydrogenation, offering significant cost and safety advantages for API manufacturing.
Novel Grignard-based route for Saxagliptin intermediate A1 offering high purity and industrial scalability for API manufacturing.
Novel preparation method for anti-drug-resistance anti-tumor EGFR inhibitor intermediates. Reduces cost, improves purity, and ensures scalable supply chain continuity.
Patent CN110106130B details a robust transaminase-PLP co-immobilized cell method for sitagliptin intermediates, offering superior stability and cost efficiency for pharmaceutical supply chains.
Novel patent CN103619867B offers high-yield estetrol intermediate synthesis with significant cost reduction and enhanced supply chain reliability for global pharmaceutical manufacturing partners.
Novel ionic liquid palladium catalysis improves yield and selectivity for dexmedetomidine intermediate manufacturing supply chain efficiency.
Novel light-induced synthesis reduces costs and improves purity for vortioxetine intermediates. Ideal for reliable pharmaceutical intermediate supply chains.
Patent CN114409505A details a high-yield synthesis of posaconazole intermediate using m-difluorobenzene, offering significant cost and supply chain advantages for API manufacturers.
Novel enzymatic N-demethylation route for Lesinurad intermediate. High yield, non-toxic reagents, scalable process for API manufacturing.
Patent CN114044758A reveals a stable synthesis route for sulfentrazone intermediates, offering cost reduction in herbicide manufacturing and enhanced supply chain reliability.
Novel azide ring-opening route for Ticagrelor Intermediate C. Reduces steps, improves purity, ensures supply chain stability for API manufacturing.